WuXi Biologics Reports Strong 2022 Interim Results
Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2...
Source: prnewswire.com
📰 Evusheld Tixagevimab News
Evusheld Tixagevimab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evusheld Tixagevimab. Real-time updates on events, politics, business and more.